Review of the pharmacotherapy of irritability of autism

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 21, Issue 2, 2012, Pages 130-146

  Elbe, Dean ^a   Lalani, Zaahira ^b  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antipsychotic; Autism; Irritability; Pharmacotherapy

Indexed keywords

AMANTADINE; ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ANTITUSSIVE AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BENZATROPINE; BIPERIDEN; CARNITINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLONIDINE; CYPROHEPTADINE; ETIRACETAM; GINKGO BILOBA EXTRACT; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LAMOTRIGINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PLACEBO; RISPERIDONE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; AGITATION; AKATHISIA; ANOREXIA; APPETITE; AUTISM; AUTOMUTILATION; BODY MASS; CAREGIVER STRAIN INDEX; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEPRESSION; DIAPHORESIS; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; EFFECT SIZE; EPISTAXIS; EYE DISEASE; FATIGUE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPOTENSION; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LETHARGY; LOW DRUG DOSE; MALE; METABOLIC PARAMETERS; MONOTHERAPY; MUSCLE RIGIDITY; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NOCTURNAL ENURESIS; NOSE CONGESTION; OCULOGYRIC CRISIS; OUTCOME ASSESSMENT; OVERT AGGRESSION SCALE MODIFIED; PARESTHESIA; POLYURIA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; RHINITIS; SCHOOL CHILD; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SORE THROAT; STOMACH DISCOMFORT; STOMACH PAIN; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 84860202258     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Akhondzadeh, S., Erfani, S., Mohammadi, M. R., Terhani-Doost, M., Amini, H., Gudarzi, S. S., & Yasami, M. T. (2004). Cyproheptadine in the treatment of autistic disorder: A double-blind placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics, 29(2), 145-150.
2. Akhondzadeh, S., Fallah J., Mohammadi M-R., Imani R., Mohammadi M., Salehi B. Forghani, S. (2010). Double-blind placebocontrolled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Progress in Neuropsychopharmacology & Biological Psychiatry, 34(1), 32-36.
3. Aman, M. G., & Singh, N. N. (1994). Aberrant Behavior Checklist-Community. East Aurora, NY: Slosson.
4. American Psychiatric Association. (2000). Autism. Diagnostic and statistical manual of mental disorders: DSM-IV-TR (4th ed., pp. 70-75). Arlington: Author.
5. Amminger, G. P., Berger, G. E., Schafer, M. R., Klier, C. Friedrich M. H., & Feucht, M. (2007). Omega-3 Fatty Acids Supplementation in Children with Autism: A Double-blind Randomized, Placebocontrolled Pilot Study. Biological Psychiatry, 61(4), 551-553.
6. Arnold, L. E., Farmer, C., Kraemer, H. C., Davies, M., Witwer, A., Chuang, S., Swiezy, N. B. (2010). Moderators, Mediators, and Other Predictors of Risperidone Response in Children with Autistic Disorder and Irritability. Journal of Child and Adolescent Psychopharmacology, 20(2), 83-93.
7. Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine Therapy for Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Autism and Developmental Disorders, 31(2), 175-181.
8. Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. Journal of the American Medical Association, 302(16), 1765-1773.
9. Davit, C. J., Hundley, R. J., Bacic, J. D., & Hanson, E. M. (2011). A pilot study to improve venipuncture compliance in children and adolescents with autism spectrum disorders. Journal of Developmental & Behavioral Pediatrics, 32(7), 521-525.
10. De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011). Metabolic and endocrine adverse effects of secondgeneration antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 26(3), 144-158.
11. Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010). Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome. Neurotherapeutics, 7(3), 258-263.
12. Frazier, T. W. (2012). Friends Not Foes: Combined Risperidone and Behavior Therapy for Irritability in Autism. Journal of the American Academy of Child and Adolescent Psychiatry, 51(2), 129-131.
13. Geier D. A., Kern, J. K., Davis, G., King, P. G., Adams, J. B., Young, J. L., & Geier, M. R. (2011). A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Medical Science Monitor, 17(6), PI15-23.
14. Gupta, S., Rimland, B., & Shilling, P. D. (1996). Pentoxifylline: Brief Review and Rationale for Its Possible Use in the Treatment of Autism. Journal of Child Neurology, 11(6), 501-504.
15. Hanley, G. P, Iwata, B. A., & McCord, B. E. (2003). Functional analysis of problem behavior: A review. Journal of Applied Behavior Analysis, 36(2), 147-185.
16. Hasanzadeh, E., Mohammadi, M-R., Ghanizadeh, A., Rezazadeh, S-A., Tabrizi, M., Rezaei, F., & Akhondzadeh, S. (2012). A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders. Child Psychiatry and Human Development, Epub ahead of Print, March 6, 2012.
17. Hellings, J. A., Zarcone, J. R., Reese, R. M., Valdovinos, M. G., Marquis, J. G., Fleming K. K., & Schroeder, S. R. (2006). A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation. Journal of Autism and Developmental Disorders, 36(3), 401-411.
18. Hollander, E., Phillips, A. T,. & Yeh, C-C. (2003). Targeted treatments for symptom domains in child and adolescent autism. Lancet, 362(9385), 732-734.
19. Hollander, E., Wasserman, S., Swanson, E. N., Chaplin, W., Schapiro M. L., Zagursky, K., & Novotny, S. (2006). A double-blind placebocontrolled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology, 16(5), 541-548.
20. Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff J., Anagnostou, E. (2010). Divalproex Sodium vs Placebo for the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorders. Neuropsychopharmacology, 35(4), 990-998.
21. Jaselskis, C. A., Cook, E. H., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322-327.
22. King, B. H., Wright, M. D., Handen, B. L., Sikich, L., Zimmerman A. W., & McMahon W. (2001). Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40(6), 658-665. Lexi-Comp Online, Hudson, OH: Lexi-Comp; 2007 (accessed February 13, 2012).
23. Luby, J., Mrakotsky, C., Stalets, M. M., Belden, A., Heffelfinger, A., Williams, M., & Spitsnagel E. (2006). Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. Journal of Child and Adolescent Psychopharmacology, 16(5), 575-587.
24. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R., Carson, W. H., & Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of American Academy of Child and Adolescent Psychiatry, 48(11), 1110-1119.
25. Miral, S., Gencer, O., Inal-Emiroglu, F. N., Baykara, B., Baykara, A., & Dirik, E. (2008). Risperidone versus haloperidol in children and adolescents with AD. European Child and Adolescent Psychiatry, 17(1), 1-8.
26. Nagaraj, R., Singhi, P., & Malhi, P. (2006). Risperidone in children with autism: Randomized, placebo-controlled, double-blind study. Journal of Child Neurology, 21(6), 450-455.
27. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Findling, R. L. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533-1540.
28. Panagiotopoulos, C., Ronsley, R., Elbe, D., Davidson, J., & Smith, D. H. (2010). First do no Harm: Promoting an Evidence-Based Approach Atypical Antipsychotic use in Children and Adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 19(2), 124-137.
29. Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367-373.
30. Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., & Greenhill, L. (1995). Use of Methylphenidate in the Treatment of Children with Autistic Disorder. Journal of Autism and Developmental Disorders, 25(3), 283-294.
31. Remington, G., Sloman, L., Konstantareas, M., Parker, K., & Gow, R. (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology, 21(4), 440-444.
32. Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). (2002). Risperidone in children with autism and serious behavioural problems. The New England Journal of Medicine, 347(5), 314-321.
33. Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN). (2005). Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry, 162(7), 1361-1369.
34. Rezaei, V., Mohammadi, M-R., Ghanizadeh, A., Sahraian, A., Tabrizi, M., Rezazadeh, S-A., & Akhondzadeh, S. (2010). Double-blind placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuropsychopharmacology & Biological Psychiatry, 34(7), 1269-1272.
35. Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980). Toward Objective Classification of Childhood Autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders, 10(1), 91-103.
36. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone use in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), 634-641.
37. Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou E., Hollander, E. (2006). Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmcology, 21(6), 363-367.